Epigral Ltd Share Price – NSE /  BSE

Chemicals, Small Cap

Net profit of Epigral declined 37.00% to Rs 51.22 crore in the quarter ended September 2025 as against Rs 81.30 crore during the previous quarter ended September 2024. Sales declined 6.18% to Rs 587.36 crore in the quarter ended September 2025 as against Rs 626.06 crore during the previous quarter ended September 2024.

Powered by Capital Market - Live News

EBITDA declined by 26% YoY to Rs 132 crore while EBITDA margin contracted by 600 basis points to 23% in the second quarter.

Profit before tax in Q2 FY26 stood at Rs 70 crore, down by 43% from Rs 122 crore in Q2 FY25.

Maulik Patel, chairman and managing director, Epigral, said: This quarter ended with lower revenue on account of low sales volume and drop in realization of few products.

Volume drop was majorly on account of extended monsoon which is off season for few products. Overall plant utilization stood at 75% for H1FY26 and we expect utilization to improve in H2FY26, as extended monsoon is over and maintenance work at plant is also completed, resulting in better H2 compared to H1.

Our project to expand capacity of CPVC, Epichlorohydrin and Wind Solar Hybrid power plants are moving as per schedule and expected to be commissioned within committed timelines.

These projects will drive growth from FY2027 onwards. We have further moved a step closer for the new projects. We will be announcing the same once it is freezed and approved by the board.?

Epigral, formerly known as Meghmani Finechem, is a leading integrated manufacturer of chemicals in India. Epigral?s Dahej facility is a backward and forward integrated and automated complex with a well-planned infrastructure. In India, Epigral is the first to set up an Epichlorohydrin plant and largest capacity plant of CPVC. Epigral is also a leading manufacturer of caustic soda, caustic potash, chloromethanes, hydrogen peroxide, chlorine and hydrogen.

Powered by Capital Market - Live News

Epigral will hold a meeting of the Board of Directors of the Company on 10 November 2025.

Powered by Capital Market - Live News

In a regulatory filing, the company said that Jain?s resignation will be effective from the close of business hours on 30 September 2025.

Epigral is primarily engaged in manufacturing and selling of Chlor Alkali & its Derivatives.

The company?s consolidated net profit surged 87.1% to Rs 160.69 crore despite 6.9% decline in revenue from operations to Rs 606.54 crore in Q1 FY26 over Q1 FY25.

Shares of Epigral shed 0.67% to Rs 1,785 on the BSE.

Powered by Capital Market - Live News